STOCK TITAN

PNC extends Integrated BioPharma (INBP) line of credit to July 2026

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Integrated BioPharma, Inc. reported that PNC Bank extended the expiration date of its line of credit, documented in an April 15, 2025 promissory note, from April 15, 2026 to July 14, 2026. The extension, which also covers subsidiary Manhattan Drug Company, Inc., becomes effective on April 16, 2026.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Notification date April 14, 2026 Date PNC notified the companies of the extension
Original expiration date April 15, 2026 Initial expiration date of the line of credit
New expiration date July 14, 2026 Extended expiration date of the line of credit
Effective date of extension April 16, 2026 Date on which the extension becomes effective
Line of Credit financial
"the Companies' Expiration Date of the Line of Credit with PNC"
A line of credit is a flexible borrowing arrangement that lets a company draw money up to a preset limit, repay it, and borrow again as needed—similar to a business credit card or an emergency tap on a savings account. It matters to investors because it shows how a firm manages short-term cash needs and growth funding without taking a single large loan; access, cost, and attached conditions can affect liquidity, interest expenses and financial risk.
promissory note financial
"as set forth in a promissory note executed and delivered"
A promissory note is a written IOU in which one party promises to pay a specific sum, often with interest, to another party by a set date or on demand. Investors care because it functions like a loan: it creates a legal claim on future cash flows, carries credit and timing risk, and can affect valuation or liquidity—think of it as a formal, tradable promise to be repaid that can be assessed like any other debt investment.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Other Events regulatory
"8.01 Other Events. On April 14, 2026, Integrated BioPharma, Inc."
false 0001016504 0001016504 2026-04-14 2026-04-14
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
_________________
 
FORM 8-K
 
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
 
April 14, 2026
________________
 
INTEGRATED BIOPHARMA, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
 
Delaware
 
(STATE OR OTHER JURISDICTION OF INCORPORATION)
 
               
   001-31668
 22-2407475
(COMMISSION FILE NUMBER)
(I.R.S. EMPLOYER IDENTIFICATION NO.)
 
225 Long Avenue
Hillside, New Jersey 07205
 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
 
(973) 926-0816
(REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
 
 
 
Securities registered pursuant to Section 12(b) of the Exchange Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
None
None
None
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
     
 
 
 
 
 

 
 
8.01 Other Events.
 
On April 14, 2026, Integrated BioPharma, Inc. (the "Company") and Manhattan Drug Company, Inc. ("MDC"), a wholly owned subsidiary of the Company (collectively, the "Companies"), received notification from PNC Bank, National Association ("PNC") that the Companies' Expiration Date of the Line of Credit with PNC, as set forth in a promissory note executed and delivered by the Companies to PNC  dated April 15, 2025, has been extended from April 15, 2026 to July 14, 2026, or such late date as may, in PNC's sole discretion, be designated by PNC by written notice from PNC to the Companies, effective on April 16, 2026.
 
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
The following exhibit relating to Item 8.01 shall be deemed to be furnished, and not filed:
 
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-1-

 
 
 
 
EXHIBIT INDEX
 
     
Exhibit
  
Description
   
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-2-

 
 
 
 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
  INTEGRATED BIOPHARMA, INC.
   
Date: April 15, 2026
By:     /s/ Dina L Masi
 
           Dina L. Masi
 
           Chief Financial Officer
 
                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

-3-

FAQ

What did Integrated BioPharma (INBP) disclose in its latest 8-K?

Integrated BioPharma disclosed that PNC Bank extended the expiration date of its line of credit from April 15, 2026 to July 14, 2026. The change applies to the company and its subsidiary Manhattan Drug Company, Inc. and becomes effective on April 16, 2026.

Which lender extended Integrated BioPharma (INBP)’s line of credit?

The line of credit for Integrated BioPharma and its subsidiary is with PNC Bank, National Association. PNC notified the companies on April 14, 2026 that the expiration date was being extended, with the extension effective on April 16, 2026.

How long was Integrated BioPharma (INBP)’s credit line extended?

The expiration date of Integrated BioPharma’s line of credit was extended from April 15, 2026 to July 14, 2026. PNC Bank also allowed for a later date to be designated at its sole discretion by written notice to the companies.

When does the extension of Integrated BioPharma (INBP)’s credit line take effect?

The extension of the line of credit’s expiration date becomes effective on April 16, 2026. This change modifies the original April 15, 2026 expiration and now runs through July 14, 2026, unless PNC designates a later date in writing.

Which subsidiaries of Integrated BioPharma (INBP) are covered by the credit line?

The credit line extension applies to Integrated BioPharma, Inc. and Manhattan Drug Company, Inc. Manhattan Drug Company is a wholly owned subsidiary, and together they are the borrowers under the April 15, 2025 promissory note with PNC Bank.

Filing Exhibits & Attachments

4 documents